Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program.


Journal

Journal of clinical lipidology
ISSN: 1933-2874
Titre abrégé: J Clin Lipidol
Pays: United States
ID NLM: 101300157

Informations de publication

Date de publication:
Historique:
received: 08 01 2020
revised: 20 03 2020
accepted: 29 03 2020
entrez: 13 6 2020
pubmed: 13 6 2020
medline: 7 8 2021
Statut: ppublish

Résumé

Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age. The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients. The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years. Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, than non-FH patients. Before adjustment, their 5-year survival and event-free survival did not differ from non-FH patients. After adjustment, however, both mortality (hazard ratio [HR] 1.82, 95% confidence interval [CI] 1.15-2.89; P = .011) and the combined endpoint of death, AMI, or stroke (HR 2.22, 95% CI: 1.51-3.26; P < .001) were higher in FH patients. The higher risk in FH patients was also present in patients receiving high-intensity lipid-lowering therapy at discharge: adjusted HR for mortality 2.29, 95% CI: 1.18 to 4.47, P = .015; HR for cardiovascular events 2.57, 95% CI: 1.48 to 4.48, P = .001. Concordant results were observed in propensity score-marched cohorts. The risk of long-term mortality and cardiovascular events is twice as high in FH than in non-FH patients, when adjusted on baseline characteristics, even for those receiving high-intensity lipid-lowering therapy. Additional therapeutic measures are needed in these patients.

Sections du résumé

BACKGROUND
Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age.
OBJECTIVES
The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients.
METHODS
The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years.
RESULTS
Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, than non-FH patients. Before adjustment, their 5-year survival and event-free survival did not differ from non-FH patients. After adjustment, however, both mortality (hazard ratio [HR] 1.82, 95% confidence interval [CI] 1.15-2.89; P = .011) and the combined endpoint of death, AMI, or stroke (HR 2.22, 95% CI: 1.51-3.26; P < .001) were higher in FH patients. The higher risk in FH patients was also present in patients receiving high-intensity lipid-lowering therapy at discharge: adjusted HR for mortality 2.29, 95% CI: 1.18 to 4.47, P = .015; HR for cardiovascular events 2.57, 95% CI: 1.48 to 4.48, P = .001. Concordant results were observed in propensity score-marched cohorts.
CONCLUSIONS
The risk of long-term mortality and cardiovascular events is twice as high in FH than in non-FH patients, when adjusted on baseline characteristics, even for those receiving high-intensity lipid-lowering therapy. Additional therapeutic measures are needed in these patients.

Identifiants

pubmed: 32527469
pii: S1933-2874(20)30070-2
doi: 10.1016/j.jacl.2020.03.008
pii:
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-360.e6

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Nicolas Danchin (N)

Department of Cardiology, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France. Electronic address: nicolasdanchin@yahoo.fr.

Michel Farnier (M)

Department of Cardiology, Hôpital du Bocage, EA 7460 Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2), Université de Bourgogne-Franche Comté, Dijon, France.

Marianne Zeller (M)

Department of Cardiology, Hôpital du Bocage, EA 7460 Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2), Université de Bourgogne-Franche Comté, Dijon, France.

Etienne Puymirat (E)

Department of Cardiology, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France.

Yves Cottin (Y)

Department of Cardiology, Hôpital du Bocage, EA 7460 Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2), Université de Bourgogne-Franche Comté, Dijon, France.

Loïc Belle (L)

Department of Cardiology, Centre Hospitalier Annecy Genevois, Annecy, France.

Gilles Lemesle (G)

USIC et Centre Hémodynamique, Institut Cœur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France; Faculté de Médecine de l'Université de Lille, Lille, France; INSERM UMR 1011, Institut Pasteur de Lille, Lille, France; FACT (French Alliance for Cardiovascular Trials), Paris, France.

Guillaume Cayla (G)

Department of Cardiology, Centre Hospitalier Universitaire de Nîmes, Université de Montpellier, Nîmes, France.

Patrick Ohlmann (P)

Department of Cardiology, Centre Hospitalier Universitaire de Strasbourg, Université de Strasbourg, Strasbourg, France.

Laurent Jacquemin (L)

Department of Cardiology, Hôpital Emile Muller, Mulhouse, France.

Thibault Perret (T)

Department of Cardiology, Hôpital Saint Joseph et Saint Luc, Lyon, France.

Denis Angoulvant (D)

Department of Cardiology, Hôpital Trousseau, Université de Tours, Tours, France.

Franck Albert (F)

Department of Cardiology, Centre Hospitalier de Chartres, Le Coudray, France.

Jean Ferrières (J)

Department of Cardiology, Hôpital Jean Minjoz, Toulouse University Hospital, Toulouse University School of Medicine, INSERM UMR 1027, Toulouse, France.

François Schiele (F)

Department of Cardiology, Hôpital Jean Minjoz, Hôpital Jean Minjoz, Université de Bourgogne-Franche-Comté, Besançon, France.

Tabassome Simon (T)

Department of Pharmacology, Hôpital St Antoine, Université Pierre et Marie Curie, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH